MiR-125a promotes paclitaxel sensitivity in cervical cancer through altering STAT3 expression

Mostrar otras versiones (1)

Cervical cancer (CC) is one of the most common malignancies in women. Paclitaxel is the front-line chemotherapeutic agent for treating CC. However, its therapeutic efficacy is limited because of chemoresistance, the mechanism of which remains poorly understood. Here, we used microRNA (miRNA) arrays...

Descripción completa

Detalles Bibliográficos
Autores principales: Fan, Z, Cui, H, Yu, H, Ji, Q, Kang, L, Han, B, Wang, J, Dong, Q, Li, Y, Yan, Z, Yan, X, Zhang, X, Lin, Z, Hu, Y, Jiao, S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5154343/
https://www.ncbi.nlm.nih.gov/pubmed/26878391
http://dx.doi.org/10.1038/oncsis.2016.1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5154343/
https://www.ncbi.nlm.nih.gov/pubmed/26878391
http://dx.doi.org/10.1038/oncsis.2016.1

Ejemplares similares